Nateglinide-containing preparation
The present invention provides a small-sized preparation that is easy to take, containing 26% or more of nateglinide and 28% or more of at least one disintegrant selected from the group consisting of carmellose or salts thereof, sodium carboxymethyl starch, croscarmellose sodium, crospovidone, partly pregelatinized starch and low-substituted hydroxypropyl cellulose, based on the total mass of the preparation. The preparation of the present invention has high contents of nateglinide, which can be absorbed immediately to exhibit a hypoglycemic action.
1. A tablet comprising nateglinide, wherein the nateglinide is contained in an amount of 50 mass % or more based on the total mass of the tablet, and at least one disintegrant selected from the group consisting of carmellose or salts thereof, sodium carboxymethyl starch, croscarmellose sodium, crospovidone, partly pregelatinized starch and low-substituted hydroxypropyl cellulose is contained, wherein the total amount of the disintegrant is 35 mass % or more based on the total mass of the tablet.
2. The tablet of claim 1 , wherein the tablet contains 60 mg or more of the nateglinide.
3. The tablet of claim 1 , wherein the disintegrant is at least one selected from the group consisting of carmellose, crospovidone, sodium carboxymethyl starch, carmellose calcium, and carmellose potassium.
4. The tablet of claim 1 , wherein the disintegrant is carmellose.
5. The tablet of claim 1 , wherein the disintegrant is a mixture of carmellose and crospovidone.
6. The tablet of claim 1 , further comprising an acidifying agent.
7. The tablet of claim 6 , wherein the acidifying agent is contained in an amount of 5 mass % or more based on the total mass of the tablet.
8. The tablet of claim 7 , further comprising a moistening agent.
9. The tablet of claim 8 , wherein the moistening agent is a surfactant or anhydrous silicon dioxide.
10. The tablet of claim 1 , comprising 51 mass % of the nateglinide, 22 mass % of carmellose as the disintegrant, and 19 mass % of crospovidone as the disintegrant, based on the total mass of the tablet.
11. The tablet of claim 1 , wherein the disintegrant comprises at least carmellose and crospovidone.
12. The tablet of claim 2 , wherein the total mass of said tablet is 100 to 250 mg.
13. The tablet of claim 2 , wherein said tablet contains 90 mg of nateglinide and the total mass of said tablet is 130 to 180 mg.
14. The tablet of claim 1 , wherein the disintegrant is crospovidone.
15. The tablet of claim 1 , wherein nateglinide is contained in an amount of 50 to 70 mass % based on the total mass of the tablet.